Skip to main content
Equibles
ABBV logo

ABBV · AbbVie Inc.

Track ABBV — free

Use ABBV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABBV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$295.03 +0.58 (+0.20%) At close · Nov 13
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$521.50B
Shares
1.77B
Volume · Nov 13 3.26M Avg daily vol (3M) 4.8M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$295.03 Open$296.58 Day$293.56–297.25 52W close$197.38–295.03 Avg vol 30d5.4M Short int15.8M · 0.9% of shares · 3.3d Short vol24% Last earningsOct 30, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Next earnings call
Feb 3, 2027 Est · unconfirmed · in 11 wks
Q3 2026 earnings call transcript
call held Oct 30, 2026
Play latest call

Latest documents

2026
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 11% as Skyrizi and Rinvoq lead growth

AbbVie reported $49.4 billion of worldwide net revenues, up 11%; Skyrizi and Rinvoq revenue rose 25% and 23% on a constant currency basis, while diluted earnings per share reached $4.79 and operating cash flow reached $14.9 billion.

Revenue $17.4B ▲ 10.3% Net income $4.22B ▲ 2167.7% Diluted EPS $2.37 ▲ 2270.0%
Read from the MD&A section
3 source passages
The company’s financial performance for the nine months ended September 30, 2026 included delivering worldwide net revenues of $49.4 billion, operating earnings of $16.7 billion, diluted earnings per share of $4.79 and cash flows from operations of $14.9 billion. Worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis. Net revenues for Skyrizi increased 23% for the three months and 25% for the nine months ended September 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications. Net revenues for Rinvoq increased 24% for the three months and 23% for the nine months ended September 30, 2026 primarily driven by continued strong market share uptake as well as market growth across all indications. Open the document at this passage
Nov 2
Current report 8-K Events of Oct 28
Director or officer change, or executive pay

Jennifer L. Davis will resign from AbbVie Inc.’s Board effective November 2, 2026, following her appointment as Chief Executive Officer at Align Technology, Inc.; AbbVie said the resignation resulted from no dispute or disagreement.

Oct 30
Earnings call
AbbVie raises guidance and dividend after strong growth

AbbVie reported adjusted earnings per share of $3.82 and total net revenues of $17.4 billion, raised revenue guidance to approximately $67.8 billion, and increased its quarterly dividend 5.2% to $1.82 per share, beginning February 2027.

Read from the first part of this long document
4 source passages
AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Turning to our third-quarter performance, we achieved adjusted earnings per share of $3.82, which is $0.07 above our guidance midpoint. Total net revenues were $17.4 billion, beating our expectations by $200 million and reflecting robust sales growth of more than 10%. We now expect total net revenues of approximately $67.8 billion, an increase of $200 million. This robust free cash flow supports a strong and growing quarterly dividend, which we are increasing 5.2% to $1.82 per share, beginning with a dividend payable in February of 2027 Open the document at this passage
Oct 30
Current report 8-K
Financial results

AbbVie reported third-quarter net revenues of $17.404 billion, GAAP diluted EPS of $2.37 and adjusted diluted EPS of $3.82; raised 2026 adjusted diluted EPS guidance to $13.95 - $13.99 and completed its acquisition of Apogee Therapeutics.

Oct 15
Current report 8-K Events of Oct 14
Director or officer change, or executive pay

AbbVie expanded its Board from twelve to thirteen directors on October 14, 2026 and appointed Dr. John M. Carethers as a Class II independent director, placing him on the Public Policy and Sustainability Committee.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$66.01B
Trailing 12 months
Net income (TTM)
$10.34B
Trailing 12 months
Revenue growth YoY
+10.3%
Year over year
Operating margin
32.2%
Trailing 12 months
P / E (TTM)
50.8
Trailing earnings · reciprocal yield 2.0%
FCF yield
3.6%
TTM · current market cap
Return on invested capital
26.2%
Trailing 12 months
Net cash
−$70.13B
Latest balance sheet
Dividend yield
2.3%
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
+27.0%
Trailing year
Short interest
0.9%
Latest settlement · 3.3 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲5.6% $15.10B −$22.00M '24 Q4 ▲8.4% $13.34B $1.29B '25 Q1 ▲6.6% $15.42B $938.00M '25 Q2 ▲9.1% $15.78B $186.00M '25 Q3 ▲10% $16.62B $1.82B '25 Q4 ▲12.4% $15.00B $695.00M '26 Q1 ▲10.2% $16.99B $3.61B '26 Q2 LATEST ▲10.3% $17.40B $4.22B '26 Q3

AI Brief

Q3 FY26 earnings call · Oct 30, 2026
Q3 FY26

TL;DR. AbbVie reported $17.404 billion of third-quarter revenue and $3.82 of adjusted EPS, raised full-year revenue and EPS guidance, and posted strong immunology and neuroscience growth. Skyrizi Crohn’s and Juvmo approvals and major oncology readouts advanced the pipeline, while free cash flow supported a 5.2% dividend increase; Humira, Imbruvica, aesthetics, acquired IPR&D expense, and Vraylar’s 2027 IRA pricing remained headwinds.

Bullish
Bearish
  • − Humira sales fell 30.6% operationally because of continued biosimilar competition.
  • − Acquired IPR&D and milestone expense reduced third-quarter adjusted EPS by $0.11 per share. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Research

our published analysis of this company

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +23%
above
Price vs 50-day avg +7%
above
RSI (14) 63
neutral
MACD trend Negative
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +3%
trailing
6-month return +38%
trailing
YTD return +29%
this year
Relative strength +38%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $276 › 200d $241 — 50d above 200d
Institutional flow Accumulating
3,919 of 4,275 funds reported for Sep 30 · net +6.4M sh shares · +133 new
Insider flow Distributing
Net -$11.9M over 90 days · 100% sells
Short interest Rising
0.89% of shares out · ▲ +1.5% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
4,275 holders — near 3-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Fair
Revenue growth +9%
Y/Y
EPS growth −1%
Y/Y
Free cash flow $17.8B
Valuation P/E 50.8
rich
Buyback $1.8B
remaining
Balance sheet $59.8B
net debt
Quant / Vol
risk profile
Moderate
Volatility 25%
annualized · 1-yr
Max drawdown −16%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 8
Latest guidance · from the Earnings Call filed Oct 30, 2026
beginning with the dividend payable in February 2027
Quarterly cash dividend 5.2%
long-term
Parkinson's therapies to collectively deliver peak sales at least $5B
peak sales
These two new indications combined are expected to contribute pe $2B
full-year
Full-year adjusted earnings per share guidance range Non-GAAP $13.95 – $13.99
Total net revenues $67.8B
Favorable impact from foreign exchange on full-year sales growth 0.5%
Full-year adjusted gross margin Non-GAAP at least 84%
Adjusted SG&A expense Non-GAAP $14.5B
Adjusted R&D expense Non-GAAP $9.8B
Adjusted operating margin Non-GAAP 46.7%
fourth quarter
Adjusted earnings per share Non-GAAP $3.83 – $3.87
Net revenues $18.4B
beginning with a dividend payable in February of 2027
Quarterly dividend $1.82
into the 2030s
Three $5 billion plus franchises at least $5B
Previous outlook earlier release · from the Earnings Call filed Jul 31, 2026

Still-open targets the latest release did not restate under the same label.

Total net revenues · full year $67.6B
SkyRisi global revenues · full year $21.7B
Total neuroscience revenues · full year $12.7B
Adjusted R&D expense · full year $9.8B
Adjusted net interest expense · full year $2.9B
Prior guidance period ended · from the 8-K filed Oct 5, 2026
Adjusted diluted earnings per share guidance range · third-quarter 2026 $3.73 – $3.77
Guided vs delivered · last 8 settled
Net revenues second quarter 2026
guided $16.7B
$16.99B Beat +1.7%
Net revenues first quarter
guided $14.7B
$15B Beat +2.1%
Total net revenues full year
guided $60.5B
$61.16B Beat +1.1%
Net revenues third quarter
guided $15.5B
$15.78B Beat +1.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+23% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
63 Neutral
MACD trend
Negative Bearish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $276 › 200d $241 — 50d above 200d
Institutional flow Accumulating
3,919 of 4,275 funds reported for Sep 30 · net +6.4M sh shares · +133 new
Insider flow Distributing
Net -$11.9M over 90 days · 100% sells
Short interest Rising
0.89% of shares out · ▲ +1.5% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
4,275 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $197 Now $295 · 100% Range high $295
vs 200-day avg +23% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
adjusted gross margin ratio non-GAAP 85.1% third quarter —
adjusted operating margin ratio non-GAAP 48.7% third quarter —
adjusted R&D expense non-GAAP 13.9% third quarter —
adjusted SG&A expense non-GAAP 21.2% third quarter —
adjusted tax rate non-GAAP 14.5% first nine months of 2026 —
overall response rate (ORR) 74% Phase 3 CERVINO study —
progression-free survival (PFS) 60% Phase 3 CERVINO study —
risk of disease progression or death 51% Phase 3 EPCORE DLBCL-2 trial —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABBV
AbbVie Inc.
this stock
$521.50B +29.1% +8.6% 50.8 0.9%
LLY
ELI LILLY & Co
 $1.36T +34.3% +44.7% 46.9 0.8%
JNJ
Johnson & Johnson
 $687.89B +38.1% +6.0% 43.4 0.7%
MRK
Merck & Co., Inc.
 $364.26B +40.4% +1.3% 152.3 1.1%
NVS
Novartis AG
 $303.12B +16.4% — — 0.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
4,367
% held
77.2%
Reported
3,919 of 4,275
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,616
View
Short & Settlement
Short Interest Rising
Shares short
15.8M
Days to cover
3.3d
Change
+230.6K sh
View
Short Volume
Short vol %
24%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
355
Value
$99.8K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
56.1%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$11.9M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Pete Sessions
Amount
$15.0K–$50.0K
Traded
Sep 14, 2026
View
Financials
Financials
Revenue (FY)
$61.2B
Net income (FY)
$4.2B
EPS diluted
$2.36
View
Buybacks
Authorized
$10.0B
Remaining
$1.8B
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
30

AbbVie reported $49.4 billion of worldwide net revenues, up 11%; Skyrizi and Rinvoq revenue rose 25% and 23% on a constant currency basis, while diluted earnings per share reached $4.79 and operating cash flow reached $14.9 billion.

View
Proposed Sales
Value
$11.9M
Shares
40.6K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 30, 2026
View
Investor Relations
Latest news
AbbVie Reports Third-Quarter 2026…
Published
Oct 30, 2026
View

Performance

5D 20D 120D MTD YTD
ABBV +1.3% +3.4% +38.4% +0.1% +29.1%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -1.3% +4.5% +37.9% +0.2% +18.5%

Capital returns

Latest dividend
$1.73 / share · ex Oct 15, 2026
Declared · upcoming
$1.82 / share · ex Jan 15, 2027
Raised 5.5%
Paid (TTM)
$6.92 / share · 4 payouts
Dividend yield (TTM, derived)
2.35%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$10.00B
Spent (derived)
$8.20B
Remaining
$1.80B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1551152 CUSIP 00287Y109 13F (30d) 3367 filings 3202 filers Visit website Investor relations